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ABSTRACT (233 words) 
[Background] Mortality subsequent to a hospitalization for heart failure is reported to be much lower in 
Japan than in the United Kingdom (UK). This could reflect differences in disease severity or in 
management. Accordingly, we directly compared patient backgrounds and outcomes between Japan and 
UK. 
[Methods] Consecutive patients admitted to academic hospitals in the UK and Japan with heart failure 
had a common set of variables, including plasma concentrations of N-terminal pro-B-type natriuretic 
peptide (NT-proBNP), collected during admission. Mortality during hospitalizations, at 90- and 180-days 
was recorded and stratified by quintile of NT-proBNP. 
[Results] Overall, 935 patients were enrolled; 197 from UK and 738 from Japan. Median (interquartile 
range) age (UK: 78 [71−88] vs. Japan: 78 [70−84] years; p=0.947), glomerular filtration rate (UK: 49 
[34−68] vs. Japan: 49 [33−65] ml/min/1.73m2; p=0.209) and plasma NT-proBNP (UK: 4957 
[2278−10977] vs. Japan: 4155 [1972−9623] ng/L; p=0.186) were similar but systolic blood pressure 
(SBP) was lower in the UK (118 [105−131] vs. 137 [118−159] mm Hg; p<0.001). Patients with a higher 
plasma NT-proBNP had a worse prognosis in both countries; in-hospital and post-discharge mortality 
rates were higher in the UK even after adjusting for prognostic variables including NT-proBNP. 
[Conclusions] This analysis suggests that either unobserved differences in patient characteristics or 
differences in care (formal or informal) rather than greater heart failure severity may account for the 
worse outcome of heart failure in the UK compared to Japan. 
 
Keywords: Heart failure; N-terminal pro-B-type natriuretic peptide; international comparison; risk 
stratification; prognosis. 
  
Page 3 of 15 
 
INTRODUCTION 
Heart failure is a global problem but patient-outcomes are reported to differ markedly amongst 
countries,
1,2 
despite the similarity of international guidelines on management.
3-10
 This may reflect 
differences in the severity of heart failure, in the implementation of therapy, in patients’ willingness to 
adhere to advice or in ethnicity and culture. Natriuretic peptides provide an objective measure of the 
severity and prognosis of heart failure and may therefore shed some light on the reasons for observed 
differences.
11-13
 Accordingly, we compared the outcome of patients hospitalized for heart failure in Japan 
and the United Kingdom (UK) stratified by plasma concentrations of N-terminal pro-B-type natriuretic 
peptide (NT-proBNP). 
 
METHODS 
Data sources and study cohort 
The characteristics and outcomes of consecutive patients hospitalized for heart failure and who had 
NT-proBNP measured were recorded in the West Tokyo Heart Failure (WET-HF) registry and the Hull 
Lifelab registry. Data were collected during 2012 in the UK and between 2011 and 2013 in Japan. 
WET-HF is an ongoing, prospective, multi-center registry of patients admitted for heart failure to five 
academic hospitals in metropolitan Tokyo.
14
 Data are collected by trained personnel from the patients’ 
charts and entered using a web-based electronic data-capture system. The Hull Lifelab is a large, 
epidemiologically representative, information-rich data-set on the contemporary diagnosis, treatment and 
natural history of patients with heart failure with a main focus on out-patient referrals.
15
 For this analysis, 
only patients referred during a hospitalization for heart failure were included. 
The clinical diagnosis of heart failure was made by cardiologists with a special interest in 
heart failure at each institution. The British and Japanese data-sets provide similar information. Each 
study was approved by the institutional ethics review boards. In Japan, written informed consent is not 
mandatory and oral informed consent is sufficient based on government rules, for observational studies 
that use clinical information that has already been obtained as a part of usual clinical practice (the report 
from the Ministry of Health, labour and Welfare. in only Japanese.  
www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/). In contrast, written 
informed consent was obtained from all patients in the UK. 
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The following data were collected: 1) patient demographics and comorbidities; 2) vital 
symptoms and signs at presentation; 3) laboratory data including renal function and NT-proBNP 
measured within 3-5 days after admission; 4) left ventricular ejection fraction (LVEF); 5) medication at 
discharge; and 6) in-hospital mortality, 90-day and 180-day post-discharge mortality. The estimated 
glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease 
equation.
16
 
 
Statistical Analysis 
We compared patient characteristics, medication at discharge, and mortality between patients in Japan and 
UK. Categorical variables are expressed as number and percentage, and continuous variables are 
expressed as the mean ± standard deviation (SD) or the median (interquartile range [IQR]), as appropriate. 
Statistical comparisons were performed with unpaired t test or Mann-Whitney test for continuous 
variables and the Pearson’s chi-square test for categorical variables. We constructed a prognostic model 
using logistic regression models rather than Cox proportional hazard models as time-to-event was 
unknown. Mortality by quintile of plasma NT-proBNP was reported for patients from Japan and the UK; 
quintile ranges were constructed from the two populations combined. Univariate prognostic model for 
log-transformed NT-proBNP were constructed for in-hospital, 90-day and 180-day post-discharge 
mortality. A parsimonious multi-variable prognostic model for 180-day mortality (102 events) were 
constructed using country of origin and the following nine variables: age, ischaemic heart disease, 
systolic blood pressure, haemoglobin, serum sodium, eGFR, hsCRP, LVEF, and log-transformed 
NT-proBNP. Additionally, propensity score matching analysis was performed to evaluate the influence of 
country on mortality risks after adjusting for the potential imbalance of baseline covariates between 
countries. Matching was performed using 1:1 matching protocol without replacement, using callipers of 
width equal to 0.2 of the standard deviation of the propensity score. The balance between the countries in 
the matching cohort was estimated using the absolute standard difference. All probability values were 
2-tailed, and values of p <0.05 were considered statistically significant. All statistical analyses were 
performed with SPSS version 24.0 software (SPSS Inc., Chicago, Illinois). 
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RESULTS 
Overall, 935 patients were enrolled, including 197 from the UK and 738 from Japan. All patients from the 
UK and 712 (97.0%) Japanese patients were followed-up for 180 days after discharge. The age and sex 
distribution of patients enrolled in Japan and the UK were similar (Table 1). However, British patients 
had a higher body mass index, lower systolic blood pressure (both p<0.001) and more often had 
ischaemic heart disease, chronic lung disease and a reduced LVEF compared with Japanese patients. 
However, GFR (UK: 49 [34−68] ml/min/1.73m2 vs. Japan: 49 [33−65] ml/min/1.73m2; p=0.209) and 
plasma NT-proBNP concentrations (UK: 4,957 [2,278−10,977] ng/L vs. Japan: 4,155 [1,972−9,623] 
ng/L) were similar. 
Length of hospital stay (LOHS) was longer in Japan (median [IQR], 13 [9−20] days) 
compared to the UK (median [IQR], 11 [7−18] days) (p=0.018). Fourteen (7.1%) patients in the UK died 
during hospitalization compared with 26 (3.5%) in Japan (p=0.027). Mortality rates at 90 days (25 
[13.7%] vs. 36 [5.1%]) and 180 days (39 [21.3%] vs. 57 [8.3%]) after discharge were substantially higher 
among British patients (p<0.001 for each comparison) (Figure 1). In addition, mortality rates were 
compared by LVEF above and below 45% (Figure 2): there were profound differences in the mortality 
rates between the Japan and UK cohort, especially among patients with LVEF ≥45%. Several differences 
were observed in terms of patient characteristics based on LVEF (Table S1; online supplement): among 
patients with LVEF ≥45%, the British were older and showed a higher level of blood urea nitrogen than 
that in the Japanese. Medication patterns in patients with LVEF ≥45% also differed between the 
countries. 
In univariate logistic regression models, plasma NT-proBNP was associated with both 
in-hospital and post-discharge mortality rates in Japan and UK (Table 2). Mortality rose progressively 
with each higher quintile of NT-proBNP, but within each quintile, mortality was consistently higher 
amongst British compared to Japanese patients (Figure 3). After multivariate adjustment for country as 
well as other prognostic indicators, both log-transformed NT-proBNP and country remained 
independently associated with 180-day post-discharge mortality (Table 3). Even after propensity score 
matching to further minimize the differences between British and Japanese patients (Table S2; online 
supplement), country (odds ratio 0.32; 95% confidence interval, 0.13–0.79; p=0.013) was independently 
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associated with 180-day post-discharge mortality. 
 
DISCUSSION 
This analysis suggests that the prognosis of patients hospitalized for heart failure is much better in Japan 
than in the UK but this does not appear to be due to differences in the severity of heart failure as reflected 
by plasma concentrations of NT-proBNP. Natriuretic peptides are powerful predictors of both in-hospital 
and post-discharge mortality, as confirmed for both Japanese and British patients in this study.
11,12
 
Mortality at 180 days was generally two- to three-times higher within each quintile of NT-proBNP for 
patients in the UK compared to Japan. 
Patients from the UK had several features associated with a worse prognosis including a 
higher prevalence of ischaemic heart disease and chronic lung disease, lower systolic blood pressure and 
serum sodium and higher serum urea and hsCRP but also had other features associated with a better 
prognosis including higher BMI and haemoglobin and slower heart rate. Risk models using similar 
clinical variables have been shown to be powerful prognostic markers both in Japanese patients and those 
of European descent.
13,14
 However, statistical adjustment in this analysis indicated that observed 
characteristics only partly accounted for differences in outcome in Japan compared to the UK. There were 
some treatment differences, including greater use of loop diuretics, ACE inhibitors or angiotensin 
receptor blockers, MRA and digoxin in the UK and greater use of calcium channel blockers in Japan, 
perhaps due to a higher prevalence of hypertension as reported in other studies in Japan.
17,18
 However, 
treatment differences did not appear large enough to account for the substantially worse outcome of 
British patients, especially among patients with preserved ejection fraction, although they might perhaps 
suggest that patients from the UK had more advanced heart failure. 
Our data are derived from just a few hospitals but they do appear to reflect national data in 
their respective countries. In Japan, LOHS was shorter in this study compared to historical reports,
19
 
although LOHS may be falling for heart failure in Japan.
20
 Despite a longer LOHS in Japan, which 
increases the risk of in-patient mortality due to the exposure to a greater number of days at risk, in-patient 
mortality was lower in Japan. An analysis of data from the United States have suggested hat LOHS is 
associated with an early readmission after discharge,
21
 which leads to a higher post-discharge mortality.
22
 
However, the National Audit for England & Wales suggested that longer LOHS was associated with an 
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adverse post-discharge prognosis, probably reflecting more severe disease amongst those with longer 
LOHS.
23
 We could not identify such a relationship either for Japanese or British patients in our study. 
This may reflect the inability to show small differences due to sample size, differences in reasons for 
LOHS or post-discharge care in Japan and the UK compared to the United States or the absence of any 
important relationship.
 
LOHS did not result in more patients being discharged on 
renin-angiotensin-aldosterone system inhibitors or beta-blockers and, historically, patients in Japan are 
generally treated with lower doses of medication and thus it is difficult to attribute better outcomes in 
Japan to better treatment due to longer LOHS. The Acute Decompensated Heart Failure Syndromes 
(ATTEND) registry, which is the largest prospective multi-center registry in Japan, reported an in-hospital 
mortality of 6.4% and a 180-day mortality of approximately 10%,
18,24
 which is similar to the WET-HF 
registry. 
This analysis included data from only one British hospital. However, similar results were 
reported from the national audit on heart failure for England & Wales including more than 37,000 patients 
from more than 100 hospitals in 2011−12. The national audit reported a median length of stay on 
cardiology wards of 9 (IQR 5−16) days, an in-hospital mortality of 11% and a 180-day mortality of 
approximately 20%.
25
 Some reports suggest that mortality rates for patients hospitalized with heart failure 
might be higher in the UK than other European countries.
26-28
 However, the First European Heart Failure 
survey reported the outcome of >8,000 patients and suggested similar mortality of around 14% within 12 
weeks of an admission for heart failure from most of the 24 countries involved.
29
 Lower mortalities have 
been reported in some other European,
26,27
 US
28
 and Korean
30
 registries but this may reflect differences in 
case-ascertainment which can have a large effect on mortality. 
There are many deficiencies in our data that limit interpretation. The cohorts were relatively 
small but do appear representative of their respective national data. The measurement of NT-proBNP was 
usually performed several days after hospitalisation rather than on admission. However, this may have 
been an advantage as BNP measured later during an admission is a stronger marker of prognosis.
31
 
Differences in variables that were not measured or not included in the statistical model (e.g., frailty, 
nutritional status, malignancy, or chronic lung disease) may have accounted for the better prognosis of 
Japanese patients. For example, place of care is a key quality metric for HF. The data from the National 
Heart Failure Audit for England & Wales showed lower in-hospital as well as post-discharge mortality 
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rates for patients treated in Cardiology than in General Medicine or other wards.
25
 In this British cohort, 
approximately 40% of patients with HF were admitted to wards other than Cardiology such as General 
Medicine wards, and this is in agreement with the national data in the UK.
23
 However, such data were not 
obtained pertaining to Japanese patients in this study. Additionally, the national report showed that British 
patients were more likely to receive specialist follow-up by a cardiologist and/or in a heart failure clinic if 
treated in a Cardiology ward than in other wards.
23
 Therefore, these differences might have affected the 
outcomes in this study. In addition, evaluation of the mode of death might have helped clarify differences 
in the prognosis of HF patients between the two countries. Particularly among patients with preserved 
ejection fraction, further research is warranted to confirm this result by performing a study involving a 
larger population of patients with HF. A well-designed study that includes comprehensive information 
regarding biomarkers (e.g., natriuretic peptides, among other such parameters), comorbidities, frailty, 
social supports and local medical systems may provide a better understanding of the discrepancy between 
the prognosis of British and Japanese patients with HF. Doses of medication will have been lower in 
Japan than in the UK but precise data on dose throughout follow-up was not recorded. We have no data 
on patient-adherence to medical advice or differences in lifestyle choices. Ethnic or genetic differences 
might also have contributed to differences in outcome and/or response to therapy. Finally, we cannot 
exclude differences in the criteria for hospitalisation or referral to specialty services or in case-selection. 
Clearly, these preliminary data require confirmation. 
 
CONCLUSIONS 
Important differences exist in patient characteristics, management and outcomes for patients hospitalised 
with heart failure in Japan compared to the UK but the distribution and prognostic significance of 
post-admission plasma concentrations of NT-proBNP were similar. Patients in the UK had a substantially 
higher mortality even after adjusting for plasma NT-proBNP. If the reasons for the difference in mortality 
can be identified and are modifiable, this might help improve the outcome of patients with heart failure in 
the UK. 
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Figure Legends 
 
Figure 1. In-hospital, 90-day and 180-day post-discharge mortality rates for patients hospitalized for 
heart failure in Japan and The United Kingdom. 
 
Figure 2. In-hospital, 90-day and 180-day post-discharge mortality rates based on left ventricular ejection 
fraction (LVEF): (A) LVEF <45% and (B) LVEF ≥45%. 
 
Figure 3. The mortality rates according to quintiles of plasma concentration of NT-proBNP for the: (2-A) 
in-hospital mortality; (2-B) 90-day post-discharge mortality; (2-C) 180-day post-discharge mortality. 
NT-proBNP; N-terminal pro-B-type natriuretic peptide. Quintile ranges were <1641, 1641−3255, 
3255−6090, 6090−12340 and >12340 ng/L for the two populations combined. 
